Insights

The benefits of end-to-end formulation and fill-finish of biologics

icons/content-types/white paper white paper

Biologics

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate from formulation development to clinical phase production and commercial manufacturing can be daunting. Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill-finish is successful.

Download the White Paper

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us
More from Curia

icons/content-types/video webinar

Antibody-Drug Conjugate (ADC) – From Bioassay Development to Linker-Payload Constructs

In this webinar, we will discuss select examples of Curia’s experience in the ADC discovery space and how some of these challenges are overcome.

icons/content-types/article article

Accelerating Therapies With Curia From Conception to Manufacturing

Partnering with a CDMO can help streamline drug development, and certain preparations can help ensure a successful collaboration. Scott Alderucci, Curia’s Director of Process Development, explores the advantages of partnering with a CDMO to navigat...